# VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

> **NCT06873321** · PHASE4 · RECRUITING · sponsor: **Science Valley Research Institute** · enrollment: 100 (estimated)

## Conditions studied

- Peripheral Arterial Disease
- Venous Thormboembolism
- Cardiovascular Diseases
- Vascular Surgery Patient with PAD / Carotid Stenosis

## Interventions

- **DRUG:** rivaroxaban 2.5 mg bid + aspirin 100 mg
- **DRUG:** clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures

## Key facts

- **NCT ID:** NCT06873321
- **Lead sponsor:** Science Valley Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-24
- **Primary completion:** 2025-07-20
- **Final completion:** 2025-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873321, "VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT06873321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*